Draxxin (tulathromycin) Injectable Solution from Pfizer Animal Health is now approved by the U.S. Center for Veterinary Medicine and the Food and Drug Administration for the control of swine respiratory disease associated with Actinobacillus pleuropneumoniae, Pasteurella multocida and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.
“This new claim will help swine producers to better control respiratory disease,” says Steve Sornsen, DVM, director of veterinary services for Pfizer Animal Health. “Draxxin is rapidly released and absorbed from the injection site and extensively distributed, so the product acts quickly against respiratory disease. Furthermore, it provides high and long-lasting concentrations in the lung tissues providing a complete treatment and excellent efficacy treating and controlling swine respiratory disease.”
Draxxin is indicated for the treatment of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis and Mycoplasma hyopneumoniae, all five key bacterial respiratory pathogens. The product requires a low-volume dose and is available in 50, 100, 250 and 500 mL sizes.
It has been proven that Draxxin provides an extended clinical duration of activity in pigs of at least nine days after a single intramuscular dose, according to the company. “A single dose of Draxxin ensures instant compliance and fast and long-lasting therapy,” Sornsen continues. “Also, there is added benefit of handling sick animals only once to reduce their stress and speed recovery.”
Draxxin has a pre-slaughter withdrawal time of five days and should not be given to pigs that are hypersensitive to the product. Always follow the pre-slaughter withdrawal time. For more information about the proper use of Draxxin in swine operations, producers should ask their veterinarian or visit www.draxxin.com.
Source: Pfizer Animal Health